These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

573 related items for PubMed ID: 33589216

  • 1. Antipsychotic Adherence, Resource Use, and Costs Before and After the Initiation of Once-monthly Paliperidone Palmitate Therapy Among Medicaid Beneficiaries With Prior Schizophrenia Relapse.
    Zhdanava M, Lin D, Lafeuille MH, Ghelerter I, Morrison L, Lefebvre P, Joshi K.
    Clin Ther; 2021 Mar; 43(3):535-548. PubMed ID: 33589216
    [Abstract] [Full Text] [Related]

  • 2. Medication adherence, healthcare resource utilization, and costs among Medicaid beneficiaries with schizophrenia treated with once-monthly paliperidone palmitate or once-every-three-months paliperidone palmitate.
    Lin D, Pilon D, Zhdanava M, Joshi K, Lafeuille MH, Côté-Sergent A, Vermette-Laforme M, Lefebvre P.
    Curr Med Res Opin; 2021 Apr; 37(4):675-683. PubMed ID: 33507838
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia.
    El Khoury AC, Pilon D, Morrison L, Shak N, Vermette-Laforme M, Amos TB, Kim E, Lefebvre P.
    Curr Med Res Opin; 2019 Mar; 35(3):395-405. PubMed ID: 30526125
    [Abstract] [Full Text] [Related]

  • 6. Risk of subsequent relapses and corresponding healthcare costs among recently-relapsed Medicaid patients with schizophrenia: a real-world retrospective cohort study.
    Patel C, Emond B, Morrison L, Lafeuille MH, Lefebvre P, Lin D, Kim E, Joshi K.
    Curr Med Res Opin; 2021 Apr; 37(4):665-674. PubMed ID: 33507831
    [Abstract] [Full Text] [Related]

  • 7. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate.
    Joshi K, Pan X, Wang R, Yang E, Benson C.
    Curr Med Res Opin; 2016 Nov; 32(11):1873-1881. PubMed ID: 27479694
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Health Outcomes Among Patients Diagnosed with Schizophrenia in the US Veterans Health Administration Population Who Transitioned from Once-Monthly to Once-Every-3-Month Paliperidone Palmitate: An Observational Retrospective Analysis.
    Patel C, El Khoury A, Huang A, Wang L, Baser O, Joshi K.
    Adv Ther; 2019 Oct; 36(10):2941-2953. PubMed ID: 31396809
    [Abstract] [Full Text] [Related]

  • 10. A comparison of treatment patterns, healthcare resource utilization, and costs among young adult Medicaid beneficiaries with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics in the US.
    Manjelievskaia J, Amos TB, El Khoury AC, Vlahiotis A, Cole A, Juneau P.
    J Med Econ; 2018 Dec; 21(12):1221-1229. PubMed ID: 30238806
    [Abstract] [Full Text] [Related]

  • 11. Transitioning from oral risperidone or paliperidone to once-monthly paliperidone palmitate: a real-world analysis among Veterans Health Administration patients with schizophrenia who have had at least one prior hospitalization.
    El Khoury A, Patel C, Huang A, Wang L, Bashyal R.
    Curr Med Res Opin; 2019 Dec; 35(12):2159-2168. PubMed ID: 31366251
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Treatment patterns and Medicaid spending in comorbid schizophrenia populations: once-monthly paliperidone palmitate versus oral atypical antipsychotics.
    Kamstra R, Pilon D, Lefebvre P, Emond B, Joshi K.
    Curr Med Res Opin; 2018 Aug; 34(8):1377-1388. PubMed ID: 29452492
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Health care resource utilization and costs of California Medicaid patients with schizophrenia treated with paliperidone palmitate once monthly or atypical oral antipsychotic treatment.
    Pesa JA, Doshi D, Wang L, Yuce H, Baser O.
    Curr Med Res Opin; 2017 Apr; 33(4):723-731. PubMed ID: 28044455
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The Impact of Once-Monthly Paliperidone Palmitate on Healthcare Utilization Among Patients With Schizophrenia Treated in an Integrated Healthcare System: A Retrospective Mirror-Image Study.
    Mahabaleshwarkar R, Lin D, Fishman J, Blair T, Hetherington T, Palmer P, Patel C, Benson C, Joshi K, Krull C, Tcheremissine OV.
    Adv Ther; 2021 Apr; 38(4):1958-1974. PubMed ID: 33704681
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.